CareDx (CDNA) Set to Announce Earnings on Thursday

CareDx (NASDAQ:CDNA) is scheduled to be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. CareDx has set its FY 2024 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.24) by ($1.97). CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The business had revenue of $65.57 million during the quarter, compared to analyst estimates of $63.66 million. During the same quarter in the prior year, the company earned ($0.34) earnings per share. The firm’s revenue for the quarter was down 20.4% compared to the same quarter last year. On average, analysts expect CareDx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CareDx Price Performance

Shares of CDNA opened at $10.18 on Tuesday. CareDx has a 1-year low of $4.80 and a 1-year high of $12.93. The firm has a 50 day simple moving average of $9.70 and a 200-day simple moving average of $9.40.

Wall Street Analyst Weigh In

CDNA has been the subject of several recent research reports. Stephens reissued an “overweight” rating and set a $15.00 price target on shares of CareDx in a research report on Wednesday, April 17th. Craig Hallum upgraded CareDx from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $12.00 to $15.00 in a research report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.00.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.